1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
11/2 07:45
In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working with regulatory regimes in different countries, and targeting different patients wit...